Press Release Details

Cerus Corporation Invites You to Join a Webcast of its First Quarter Financial Results Conference Call

April, 26 2004

Business Editors

CONCORD, Calif.--(BUSINESS WIRE)--April 26, 2004

In conjunction with Cerus Corporation's (Nasdaq:CERS) First Quarter Financial Results release, you are invited to listen to its conference call that will be broadcast live over the Internet on May 3, 2004 at 4:30 p.m. ET with Stephen Isaacs, President and CEO, Laurence Corash, M.D., Chief Medical Officer, and Greg Schafer, Chief Financial Officer of Cerus Corporation.

What: Cerus Corporation First Quarter Financial Results with an Update on Progress and Future Outlook When: Monday, May 3, 2004 at 4:30 p.m. ET 
Where:http://www.cerus.com/pages/IR/wc.html
How: Live over the Internet -- Simply log on to the web at the address above Contact: Alexandra Santos / Cerus Corporation, 925-288-6156

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.

Cerus Corporation is developing novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs. Cerus' most advanced program is the INTERCEPT Blood System, designed to enhance the safety of the world's blood supply by inactivating viruses, bacteria, other pathogens and white blood cells. The company is also pursuing novel vaccine technologies, which are being developed to harness the power of the immune system against cancer and infectious disease.

Helinx is a trademark of Cerus Corporation.

INTERCEPT Blood is a trademark of Baxter International, Inc.

Statements in this announcement regarding regulatory filings, product development and commercial potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainty of the timing, results, and rates of enrollment of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, manufacturing, market acceptance of any products, competitive conditions and other factors discussed in the company's most recent filings with the Securities and Exchange Commission.

If you are unable to participate during the live webcast, the call will be archived on the website.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600